Ultomiris — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has unresolved symptoms of generalized myasthenia gravis (e.g., difficulty swallowing, difficulty breathing, or functional disability resulting in discontinuation of physical activity such as double vision, talking, impairment of mobility)
• The medication is prescribed by or in consultation with a neurologist

Reauthorization criteria

• Patient is age ≥ 18 years
• According to the prescriber, patient is continuing to derive benefit from Ultomiris (examples include reduction in exacerbations of myasthenia gravis, improvements in speech, swallowing, mobility, or respiratory function)
• The medication is prescribed by or in consultation with a neurologist

Approval duration

1 year